Addition to labeling of cholestyramine.
D002792:Cholestyramine Resin / Q000009:adverse effects*; D002994:Clofibrate / Q000627:therapeutic use; D004035:Diet Therapy; D004348:Drug Labeling; D015248:Gemfibrozil; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D009525:Niacin / Q000627:therapeutic use; D010421:Pentanoic Acids / Q000627:therapeutic use; D011341:Probucol / Q000627:therapeutic use; D013974:Thyroxine / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000960:Hypolipidemic Agents; D010421:Pentanoic Acids; D002792:Cholestyramine Resin; D009525:Niacin; D002994:Clofibrate; D011341:Probucol; D013974:Thyroxine; D015248:Gemfibrozil